Definitive Contract 75D30120C07986

Westat, Inc. was awarded a $30.5 million cost-plus-fixed-fee modification to an existing contract with the Centers for Disease Control and Prevention (CDC) to expand a virtual network study assessing COVID-19 vaccine effectiveness. Under the modification, Westat will extend its work through September 2023 to evaluate additional populations including children, compare benefits of extra vaccine doses, and monitor declines in effectiveness over time. The original solicitation sought to add over 3.5 million members to existing study cohorts to provide ongoing evidence for policymaking. No set-aside applies. The CDC funding will continue Westat's implementation and analysis under contract number 75D30120C07986 to investigate the trajectory of severe COVID-19 outcomes.